Oppenheimer cuts Boston Scientific price target to $65
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 21, financial news outlet Cailianshe reported that Oppenheimer, an investment bank, has lowered its price target for Boston Scientific Corporation (BSX) from $85 to $65. The revision represents a significant reduction in the analyst's valuation outlook for the medical device company. The report does not specify the reasons behind the downgrade or provide any additional context regarding the company's performance or market conditions. This type of analyst action is closely watched by investors as it can influence market sentiment and trading decisions for the stock.
Source report
Date: September 21
Oppenheimer has revised its price target for Boston Scientific, reducing it from $85 to $65.
Source
财联社Neutral / independent
Part of this Story
Multiple Analysts Cut Boston Scientific Price Targets, Citi Downgrades to Neutral